ORAL THERAPY OF VITAMIN B DEFICIENCY Russian patent published in 2016 - IPC A61K31/714 A61K31/519 A61K31/155 A61K47/08 A61P3/02 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and may be used to normalise a vitamin B₁₂ level in a patient suffering vitamin B₁₂ deficiency and an average vitamin B₁₂ level of less than 350 pg/ml. That is ensured by administering one or more oral dosage forms containing (i) N-[8-(2-hydroxybenzoyl)amino]caprylic acid or its pharmaceutically acceptable salt and (ii) vitamin B₁₂ in a patient once a day for at least 15 days; a daily total amount of N-[8-(2-hydroxybenzoyl)amino]caprylic acid or its pharmaceutically acceptable salt makes from 50 to 250 mg, whereas a daily total amount of vitamin B₁₂ makes from 0.5 to 2 mg. The patient's vitamin B₁₂ level is expected to normalise during 15 days. There are also presented a method for normalising an amount of active vitamin B₁₂ in the patient, a method for reducing a methylmalonic acid (MMA) level in the patient with high MMA levels, a method for reducing a homocysteine level in the patient with high homocysteine levels, as well as methods for normalising interpersonal variability in treating these patients.

EFFECT: group of inventions enables normalising a vitamin B₁₂ level and reducing amounts of biomarkers MMA and homocysteine in the patients suffering vitamin B₁₂ deficiency during 15 or 90 days when administering the above composition once a day.

15 cl, 6 dwg, 10 tbl, 7 ex